Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
17.03
+0.11 (0.65%)
At close: Dec 20, 2024, 4:00 PM
17.01
-0.02 (-0.12%)
After-hours: Dec 20, 2024, 7:24 PM EST
Keros Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Keros Therapeutics stock have an average target of 78.33, with a low estimate of 44 and a high estimate of 111. The average target predicts an increase of 359.95% from the current stock price of 17.03.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for KROS stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 3 | 3 | 2 |
| Buy | 3 | 3 | 3 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 8 | 8 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $102 → $63 | Buy | Maintains | $102 → $63 | +269.94% | Dec 16, 2024 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 16, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $77 → $44 | Buy | Maintains | $77 → $44 | +158.37% | Dec 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 → $47 | Strong Buy | Reiterates | $100 → $47 | +175.98% | Dec 13, 2024 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Dec 12, 2024 |
Financial Forecast
Revenue This Year
490.23K
from 151.00K
Increased by 224.66%
Revenue Next Year
64.34K
from 490.23K
Decreased by -86.88%
EPS This Year
-5.31
from -5.20
EPS Next Year
-5.26
from -5.31
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.1M | 420,000 | 109.2M | |||
| Avg | 490,232 | 64,342 | 23.0M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 600.7% | -14.3% | 169,619.1% | |||
| Avg | 224.7% | -86.9% | 35,656.0% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -5.00 | -3.70 | -2.68 | |||
| Avg | -5.31 | -5.26 | -4.77 | |||
| Low | -5.39 | -6.42 | -6.81 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.